Literature DB >> 31247117

A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin.

Christina Trueck1, Chih-Hsuan Hsin1, Oliver Scherf-Clavel2, Elke Schaeffeler3,4, Rebekka Lenssen5, Malaz Gazzaz1,6, Marleen Gersie1, Max Taubert1, Maria Quasdorff1, Matthias Schwab4,7,8, Martina Kinzig2, Fritz Sörgel2,9, Marc S Stoffel1, Uwe Fuhr1.   

Abstract

A new probe drug cocktail containing substrates of important drug transporters was tested for mutual interactions in a clinical trial. The cocktail consisted of (predominant transporter; primary phenotyping metric): 10 mg adefovir-dipivoxil (OAT1; renal clearance (CLR )), 100 mg sitagliptin (OAT3; CLR ), 500 mg metformin (several renal transporters; CLR ), 2 mg pitavastatin (OATP1B1; clearance/F), and 0.5 mg digoxin (intestinal P-gp, renal P-gp, and OATP4C1; peak plasma concentration (Cmax ) and CLR ). Using a randomized six-period, open change-over design, single oral doses were administrated either concomitantly or separately to 24 healthy male and female volunteers. Phenotyping metrics were evaluated by noncompartmental analysis and compared between periods by the standard average bioequivalence approach (boundaries for ratios 0.80-1.25). Primary metrics supported the absence of relevant interactions, whereas secondary metrics suggested that mainly adefovir was a victim of minor drug-drug interactions (DDIs). All drugs were well tolerated. This cocktail may be another useful tool to assess transporter-based DDIs in vivo.
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31247117     DOI: 10.1002/cpt.1564

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin.

Authors:  Chih-Hsuan Hsin; Marc S Stoffel; Malaz Gazzaz; Elke Schaeffeler; Matthias Schwab; Uwe Fuhr; Max Taubert
Journal:  Sci Rep       Date:  2020-07-27       Impact factor: 4.379

2.  Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine.

Authors:  Sabrina T Wiebe; Thomas Giessmann; Kathrin Hohl; Sven Schmidt-Gerets; Edith Hauel; Alen Jambrecina; Kerstin Bader; Naoki Ishiguro; Mitchell E Taub; Ashish Sharma; Thomas Ebner; Gerd Mikus; Martin F Fromm; Fabian Müller; Peter Stopfer
Journal:  Clin Pharmacokinet       Date:  2020-12       Impact factor: 6.447

Review 3.  Evaluation of Excipient Risk in BCS Class I and III Biowaivers.

Authors:  Melissa Metry; James E Polli
Journal:  AAPS J       Date:  2022-01-05       Impact factor: 4.009

4.  Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein-Mediated Drug-Drug Interactions in Healthy Volunteers.

Authors:  Takeshi Miyake; Emi Kimoto; Lina Luo; Sumathy Mathialagan; Lauren M Horlbogen; Ragu Ramanathan; Linda S Wood; Jillian G Johnson; Vu H Le; Manoli Vourvahis; A David Rodrigues; Chieko Muto; Kenichi Furihata; Yuichi Sugiyama; Hiroyuki Kusuhara
Journal:  Clin Pharmacol Ther       Date:  2020-10-09       Impact factor: 6.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.